Equities

Medicus Pharma Ltd

Medicus Pharma Ltd

Actions
  • Price (CAD)2.55
  • Today's Change0.000 / 0.00%
  • Shares traded1.03k
  • 1 Year change-56.78%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 15:34 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-16.39m
  • Incorporated2008
  • Employees--
  • Location
    Medicus Pharma Ltd100 King Street West, Suite 3400TORONTO M5X 1A4CanadaCAN
  • Phone+1 (905) 681-1925
  • Fax+1 (905) 681-1925
  • Websitehttps://medicuspharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kane Biotech Inc757.12k-5.48m14.50m--------19.16-0.0420.03740.0059-0.00550.15680.37513.23---113.43-77.89----60.5443.27-723.31-241.850.5679-4.731.43---94.42-20.26-17.29---19.41--
Pharmacielo Ltd1.62m-14.15m15.82m268.00------9.76-0.0849-0.08490.0097-0.0320.06991.3824.15---61.03---165.82---86.39---873.57--0.039-2.481.37---70.96---12.27------
Cytophage Technologies Ltd0.00-7.80m17.53m----3.32-----0.3779-0.37790.000.0978----------------------------0.2374-------25.88------
Devonian Health Group Inc9.75m-3.17m18.53m6.00--1.39--1.90-0.0216-0.02160.06650.090.442333.072.321,625,238.00-14.37-21.02-23.15-23.9630.9529.96-32.50-131.971.06-9.410.1406--1.74-5.83-33.39------
Medicus Pharma Ltd0.00-16.39m27.66m----3.07-----3.56-3.560.000.83090.00-------267.24-652.37-371.17-------------20.260.0549-------300.86------
Charlotte's Web Holdings Inc73.82m-48.98m28.35m164.00--0.6721--0.384-0.3138-0.31380.47280.26780.37281.3225.80450,149.20-24.73-25.71-28.95-29.0347.2548.98-66.35-63.111.85--0.599---14.82-1.9059.88---7.88--
Decibel Cannabis Company Inc94.96m-1.51m28.77m----0.62510.560.3029-0.0037-0.01190.22920.1040.69441.455.59---1.10-3.55-1.84-5.1929.2815.77-1.59-7.130.4066-2.960.5147--46.18--60.33---32.45--
Medipharm Labs Corp39.05m-11.93m28.77m166.00--0.6388--0.7369-0.0337-0.03370.1060.10960.63063.155.47235,241.00-19.27-32.88-23.78-39.5620.87-5.88-30.56-67.662.36--0.0143--49.4926.5256.37---49.66--
Data as of Nov 21 2024. Currency figures normalised to Medicus Pharma Ltd's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.